Viral Vectors & Particles

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have

The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have

Please note this product may be subject to fees, we invite you to contact your local office. The Claudin-9 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human Claudin-9 (NM_020982) driven by an EF1A promoter and a puromycin selection marker (Figure 1). <img style="display: block; margin-left: auto; margin-right: auto;" src="{{media url="wysiwyg/Lentivirus/78721.png"}}" alt="" width="398" height="325" /> Figure 1: Schematic of the lenti-vector used to generate the Claudin-9 Lentivirus.

Please note this product may be subject to fees, we invite you to contact your local office. The Claudin-3 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human Claudin-3 (NM_001306.4) driven by an EF1A promoter and a puromycin selection marker (Figure 1). <img style="display: block; margin-left: auto; margin-right: auto;" src="{{media url="wysiwyg/Lentivirus/78722.png"}}" alt="" width="407" height="332" /> Figure 1: Schematic of the lenti-vector used to generate the Claudin-3 Lentivirus

Please note this product may be subject to fees, we invite you to contact your local office. The Claudin-4 Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce nearly all types of mammalian cells, including primary and non-dividing cells. The particles contain a human Claudin-4 (NM_001305.5) driven by an EF1A promoter and a puromycin selection marker (Figure 1). <img src="{{media url="wysiwyg/Lentivirus/78723.png"}}" alt="" width="448" height="364" /> Figure 1: Schematic of the lenti-vector used to generate the Claudin-4 Lentivirus